thrombopoietin receptor agonists
Treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure.
Acts as a thrombopoietin receptor agonist which increases platelet production by initiating proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Distribution: Well distributed to tissues.
Protein Binding: >99%.
Metabolism and Excretion: Primarily metabolized in liver via CYP4 isoenzymes. Primarily excreted in feces (83%) with 16% being eliminated as unchanged drug.
Half-life: 27 hr.
TIME/ACTION PROFILE (plasma concentrations)
|PO||unknown||6–8 hr||24 hr|
Use Cautiously in:
GI: PORTAL VEIN THROMBOSIS
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Should not be used in patients with chronic liver disease to normalize platelet counts.
PO (Adults): 3 mg once daily for 7 days. Begin therapy 8–14 days prior to the scheduled procedure such that the procedure takes place 2–8 days after the final dose.
Tablets: 3 mg
Lab Test Considerations:
Obtain platelet count before starting therapy and not >2 days before procedure.
Davis’s Drug Guide for Nurses App + Web from F.A. Davis and Unbound Medicine covers 5000+ trade name and generic drugs. Includes App for iPhone, iPad, and Android smartphone + tablet. Handbook covers dosage, side effects, interactions, uses. Davis Drug Guide PDF. Complete Product Information.